Announced Tue, 14 Apr · 15:51 IST

Submission of Annual Secretarial Compliance Report for the year ended March 31, 2026.

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+1.9%1-day move
₹25.50
prior close
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+1.9+2.8+8.6+5.0+4.1+4.3-5.3-0.8-14.1-34.5
Up moveDown movePending
AI summary

Venmax Drugs and Pharmaceuticals Ltd has submitted its Annual Secretarial Compliance Report to BSE for the financial year ended March 31, 2026. This is a mandatory yearly filing required under SEBI's Listing Obligations and Disclosure Requirements (LODR) Regulations, where the Practicing Company Secretary certifies whether the company has complied with applicable SEBI rules, regulations, and circulars during the year. The actual report content was not accessible as the linked BSE page returned an error. No specific compliance deviations, penalties, or observations are available from the source.

Likely market impact

This is a routine annual regulatory compliance submission and typically has no material impact on the stock price unless the report flags non-compliance or significant observations, which cannot be confirmed from the available information.